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Open access under CC BY-NC-ND license.Cancer associated cachexia (CAC) is a complex multi-
organ syndrome frequently associated with various
forms of cancer. Affected patients suffer from a dramatic
loss of skeletal muscle and adipose tissue. Most cases
are accompanied by anorexia, and nutritional supple-
ments are not sufficient to stop or reverse its course.
CAC impairs many forms of therapeutic interventions
and accounts for 15–20% of all deaths of cancer patients.
Recently, several studies have recognized the impor-
tance of lipid metabolism and triglyceride hydrolysis
as a major metabolic pathway involved in the initiation
and/or progression of CAC. In this review, we explore
the contributions of the triglyceride lipases to CAC and
discuss various factors modulating lipase activity.
Cancer associated cachexia: definition, symptoms, and
mediators
Cachexia is a multifactorial syndrome that occurs in many
chronic and end stage diseases. Patients suffering from
cancer frequently show signs of mild to severe forms of
cachexia, which is referred to as cancer associated cachexia
(CAC). The severity of cachexia varies depending on the
tumor type, site, and stage [1]. CAC is prevalent in patients
suffering from gastrointestinal and pancreatic adenocarci-
noma, occurring in 80–90% of patients. It also arises in
patients suffering from other carcinomas, as well as sarco-
mas, malignant lymphoma, and acute leukemia, although
to a lesser extent [2,3]. The occurrence of cachexia relies
heavily on the host response to tumor progression, includ-
ing the activation of an immune response and associated
signaling pathways [4]. Patients suffering from CAC show
anorexia and a loss of body weight, white adipose tissue
(WAT), and skeletal muscle mass, which lead to physical
impairment [5]. Patients suffering from CAC often suffer
from profound inflammation which escalates with loss of
WAT weight and progression of CAC [6]. A negative energy
balance complicates therapeutic interventions and nutri-
tional supplements can only partially ameliorate the symp-
toms of cachexia [7–9]. Thus, it should not be confused with
anorexia. This devastating condition is estimated to be the
cause of death in up to 15% of cancer patients [1,10,11].
Despite considerable advancements in understanding
the syndrome, effective approaches for managing CAC
have been hindered by the lack of an exact definition1471-4914
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sive and thorough review of the literature, a panel of
experts recently published a consensus definition of CAC
that states ‘cancer cachexia is a multi-factorial syndrome
characterized by an ongoing loss of skeletal muscle mass
(with or without loss of fat mass) that cannot be fully
reversed by conventional nutritional support and leads
to functional impairment’ [12]. The panel recognized ca-
chexia as a progressive disorder rather than a single event
and classified the manifestation of cachexia into three
stages: pre-cachexia, cachexia, and refractory cachexia.
A recently developed scoring system will also be a valuable
tool to stage cachectic cancer patients [13], and the diag-
nostic criteria proposed in these two studies are a big step
forward for diagnosing and managing CAC. However, a
thorough understanding of metabolic mechanisms that
lead to the occurrence and progression of cachexia is
imperative for designing more effective therapies to pre-
vent, or at least ameliorate, the syndrome.
Cancer-induced weight loss is attributed mostly to loss
of WAT and skeletal muscle mass. Patients suffering from
cachexia lose on average 32% of their body weight, 75% of
their skeletal muscle, as well as 85% of total body fat [14].
The loss of muscle mass might be a result of decreased
protein synthesis, increased protein catabolism, or both
depending on the tumor or stage of CAC. Recently,
Augustsson et al. reported that both visceral and subcuta-
neous WAT is already significantly reduced in newly diag-
nosed CAC patients although they did not observe changes
in lean body mass at that time [15]. This is consistent with
previous observations indicating that at the onset of ca-
chexia WAT volume is reduced before a loss of lean mass
occurs [16] and may help in diagnosing early stages of
cachexia. Importantly, recent reports recognize a promi-
nent role for lipid metabolism and triglyceride lipases in
the initiation and/or progression of CAC [17–20]. There-
fore, in this review we focus on alterations of lipid catabo-
lism in CAC and explore specifically the role of triglyceride
lipases and their modulators in CAC.
Altered lipid metabolism in CAC
WAT is regarded as the main reservoir of lipids that are
stored mostly in the form of triacylglycerol (TAG) and serve
as a major source of energy. TAG levels in WAT are
maintained by the dynamic equilibrium of two opposing
key processes, lipogenesis and lipolysis. In the anabolic
process of lipogenesis, glucose, which is transported into
adipocytes mainly via GLUT4, is catabolized to acetyl-CoA,
Box 1. Does a tumor ‘benefit’ from the induction of
cachexia?
Although several factors and mechanisms associated with CAC have
been identified in the past decades, answers to the basic questions
of how and why tumors cause cachexia remain elusive. It could be
argued that the induction of cachexia is a stochastic process
attributable to random mutations occurring in the tumor. It would
be difficult to explain, however, why it occurs at such a high
frequency. Certainly, a very plausible explanation is found in the
association with the antitumor reaction of the host that is observed
in the majority of cases, which leads to inflammatory reactions and
the release of various cytokines. Although this is very likely to be the
cause in many cases of CAC, there is also a great number and
variety of tumors with intense host reaction that do not lead to CAC.
A third, so far not widely investigated hypothesis is that the tumor
somehow benefits from the release of substances, such as FA from
WAT, during CAC development. A rapidly developing cancer
requires glucose, lactate, FA, and amino acids, among other things,
to maintain its high energy demands and requires building blocks
for ‘biomass’ to achieve high proliferation rates. It is thus
conceivable that the tumor benefits from CAC by acquiring these
factors. Murine models of cancer have demonstrated that dietary
supplements significantly affect tumor growth [94], and the
importance of circulating FA in tumor growth has been already
reported in murine models of acute fasting or streptozotocin-
induced diabetes where increased circulating FA concentration lead
to increased tumor proliferation [95–97]. In addition, lipid-lowering
drugs such as benzafibrate induce tumor growth, probably by
inducing b-oxidation of FAs in MAC16, a cachexia-inducing
adenocarcinoma that is also characterized by increased FA levels
in serum [98]. Benzafibrate does not affect tumor growth of non-
cachexia-inducing MAC13 adenocarcinoma, presumably because
FA serum levels are not increased in this model [98]. Eicosapentae-
noic acid inhibits tumor-induced lipolysis and also decreases the
growth of MAC16 tumors [99]. The fact that some rapidly
proliferating human tumors are associated with CAC further
supports this hypothesis. By contrast, the development of severe
CAC in patients with a relatively small tumor burden is also well
documented. In summary, it is very likely that the diversity in
genetic changes in tumors results in diversity of tumor metabolism
that leads to many ways of inducing CAC and potential benefits for
tumor growth.
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to generate fatty acids (FAs). Three FAs are then esterified
to a single glycerol molecule to create a molecule of TAG and
stored as an energy reserve in WAT. In addition to de novo
lipogenesis, WAT imports FAs by catabolizing circulating
lipoproteins into FA via membrane-bound lipoprotein lipase
(LPL). These FAs are imported in the cytoplasm via the
action of FA transporters and FA-binding proteins and are
subsequently re-esterified into TAG. Conversely, TAG mole-
cules stored in WAT are broken down into FAs and glycerol
by a highly regulated process known as lipolysis, a process of
three subsequent steps catalyzed by three essential lipases.
Adipose triglyceride lipase (ATGL) catalyzes the rate-limit-
ing first step, converting TAG into diacylglycerol (DAG) and
a free FA. DAG is then acted upon by hormone sensitive
lipase (HSL) to remove the second FA to form monoacylgly-
cerol (MAG). The third and final enzyme, monoglyceride
lipase (MGL) converts MAG into glycerol and a third free
FA. Thus, three molecules of FA are released in this process
that are then either re-esterified to form new TAG or shut-
tled to metabolically active tissues where they undergo fatty
acid oxidation to generate energy or might be used for
anabolic processes. Lipolysis is influenced by several addi-
tional factors that regulate the activities of these essential
lipases, and both lipoloysis and lipogenesis not only regulate
the homeostasis of WAT but also direct systemic energy
production.
Recent studies in animal models of CAC and observa-
tion of human WAT have confirmed that fat loss in cachex-
ia is a consequence of TAG depletion and not due to cell
death [21]. The processes leading to the depletion of TAG
reserves involve decreased lipogenesis, decreased FA
transport, and, most prominently, increased lipolysis [5].
Trew and Begg were the first to identify a severe deregu-
lation of lipogenesis in WAT using an animal tumor model
[22]. This observation was confirmed in many subsequent
studies, which also identified declines in the activities of
key lipogenic enzymes in WAT, such as fatty acid synthase,
citrate cleavage enzyme, and malic enzyme, associated
with tumor progression in murine cachexia models [23].
In stark contrast to these results, lipogenesis was reported
to be either upregulated in WAT of mice bearing colonic
adenocarcinoma [24] or no significant change was detected
in WAT of tumor bearing patients [21,25]. However, Notar-
nicola et al. recently showed that both mRNA levels and
the activity of FA synthase are reduced in WAT adjacent to
the tumor, compared with distant WAT, in samples from
32 colorectal cancer patients [26]. Differences in the ana-
tomical origin of WAT and/or differences in cancer types
might explain these discrepancies.
Elevated levels of serum TAG and cholesterol are often
detected in patients suffering from CAC [5], and a marked
increase in FA and glycerol concentrations are observed in
cancer patients suffering from cachexia as compared to
weight-stable cancer patients [27–30]. Murine models of
CAC also show increased serum levels of FA and glycerol,
suggesting increased TAG catabolism and delipidation of
fat reserves [18]. Ryden et al. have confirmed these findings
and state that increased lipolysis and not cell death or
impaired lipogenesis is involved in WAT loss in cachectic
patients [21]. Similarly, TAG hydrolase activity in visceralWAT of cancer patients shows a strong negative correla-
tion with body mass index (BMI), whereas such a correla-
tion is absent in patients without tumor [18]. Observations
made by several other groups, including us, in patient
samples and animal models of cachexia reinforced the
hypothesis that increased lipolysis is a major determinant
of adipose tissue loss in CAC [18,21,28,29]. This observa-
tion is also supported by a comprehensive transcriptomics
analysis of adipose tissue describing a significant upregu-
lation of genes involved in the FA degradation pathway, as
well as genes involved in the tricarboxylic acid cycle (TCA)
cycle and the oxidative phosphorylation (OXPHOS) path-
way in CAC patients [31]. In conclusion, cancer shifts lipid
metabolism to a catabolic state, thus decreasing the fat
mass in cachectic patients. As a result, systemic lipid
metabolism is severely disturbed which, in turn, might
cause lipotoxic effects in other tissues including skeletal
muscle (Box 1). Indeed Stephens et al. observed that
intramyocellular lipid droplets increased in size and num-
ber in the course of cachexia progression in cancer patients
[32]. This is supported by our observations of increased
TAG concentrations in Musculus gastrocnemius of Lewis
lung carcinoma (LLC) bearing cachectic mice [18].293
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downregulation of key adipogenic factors: CCAAT/enhancer
binding protein b (C/EBPb), C/EBPa, peroxisome prolifera-
tor-activated receptor g (PPARg), and sterol regulatory
element-binding protein-1c (SREBP-1c) [33]. Figure 1 illus-
trates various tumor associated mechanisms that may in-
fluence lipid homeostasis in WAT and lead to CAC.White a
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Figure 1. Altered lipid metabolism in cancer associated cachexia (CAC). Malignant tumo
(TNF-a), lipid-mobilizing factor (LMF)/Zinc-a2 glycoprotein (ZAG), and an unknown cache
(WAT) and deregulate lipid metabolism. TNF-a acts through the TNF receptor (TNF-r) and 
adipose triglyceride lipase (ATGL) activity. Therefore, TNF-a can increase ATGL activity. AT
the first step of lipolysis by converting triacylglycerol (TAG) present in lipid droplets to dia
sensitive lipase (HSL) and is converted into monoacylglycerol (MAG). As the final step of
which can be released into circulation. One molecule of free fatty acid (FFA) is generate
dependent protein kinase 1 (cGK1). PKA can be activated by catecholamine or LMF/ZAG
processes. FA generated by increased lipolysis can be transported out of the adipocytes o
increases the level of pyruvate dehydrogenase complex (PDC) and, hence, assists in b-ox
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and results in macrophage infiltration in WAT often seen in cachexia. Factors in red are 
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Lipoprotein lipase (LPL)
LPL is a member of the triglyceride hydrolase family and is
attached to the surface of endothelial cells most abundant-
ly in WAT, skeletal muscle, and heart. LPL hydrolyzes
TAG present in circulating very-low-density lipoproteins
(VLDLs) and chylomicrons (lipoprotein particles very richDG
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rs release various cytokines including interleukin (IL)-6 and tumor necrosis factor-a
xia inducing factor (CIF) in circulation. All these factors act on white adipose tissue
downregulates G0S2 (G0/G1 switch gene 2), which binds to and negatively regulates
GL, along with its coactivator CGI-58 (comparative gene identification-58), catabolizes
cylglycerol (DAG). DAG is further acted upon by activated (phosphorylated) hormone
 the lipolytic process, monoglyceride lipase (MAGL) converts MAG into glycerol (G)
d in each of the steps. HSL is phosphorylated by protein kinase A (PKA) or cGMP-
 through various mechanisms. Similarly, glucocorticoids activate cGK1 by various
r b-oxidized in mitochondria. CIF induces cell death activator (CIDEA), which, in turn,
idation. Along with TNF-a, IL-6 also induces lipolysis, although the mechanisms are
s FA uptake by inhibiting lipoprotein lipase (LPL) activity, leading to decreased TAG
rotein (VLDL/LDL) levels in circulation. Increased lipolysis also attracts macrophages
upregulated in cachexia, those in green are downregulated in cachexia, and factors
dicate pathways confirmed in CAC and dotted lines expected but unconfirmed ones.
Review Trends in Molecular Medicine May 2013, Vol. 19, No. 5in triglycerides). Free FAs are subsequently transported
directly into parenchymal cells. Increased circulating TAG,
low-density lipoproteins (LDLs), and VLDL in cancer
patients as well as in animal models of CAC suggest the
downregulation of LPL activity.
Obeid and Emery found decreased LPL activity early
during progressive tumor growth in mice [34], and de-
creased LPL activity is also reported in patients suffering
from gastric and colorectal carcinoma, but not in breast
carcinoma patients [35]. Interestingly, circulating levels of
interleukin (IL)-6 did not correlate with LPL activity in
these patients. Similarly, a decrease in LPL activity was
noted in later stages of tumor cachexia in mice bearing
MAC16 adenocarcinoma [36]. Leukemia inhibitory factor
(LIF) and tumor necrosis factor-a (TNF-a) are both
reported to decrease the activity as well as mRNA expres-
sion of LPL in cultured adipocytes [37,38]. Thus, increased
circulating levels of LIF and TNF-a in CAC patients and
mice models might explain decreased LPL activities. In
addition, Nara-Ashizawa et al. have reported the presence
of a factor that seems to be different from the well-known
cytokines involved in cachexia, IL-1b, IL-6, IL-1, TNF-a,
transforming growth factor-b (TGF-b), and LIF [39].
Treatment with benzafibrate, an antihyperlipidemic
drug, has been shown to enhance LPL activity in tumor
bearing rats, which resulted in the preservation of epidid-
ymal WAT and partial prevention of hyperlipidemia [40].
Similar effects have been shown for NO1886 and pronalre-
stat in B16 melanoma-induced cachexia [41,42]. These
promising effects have, unfortunately, not yet been trans-
lated into successful treatment strategies for CAC
patients.
Hormone sensitive lipase (HSL)
Although fasting-induced lipolysis in WAT had been
known for several decades, HSL was the first lipase to
be discovered that is responsive to fasting and regulated by
catabolic hormones [43]. HSL has a relatively broad sub-
strate specificity, hydrolyzing DAG, cholesterol ester, reti-
noic ester, TAG, MAG, as well as short chain carbonic
esters and ester substrates [44], although several studies
indicate that DAG is a much better substrate for HSL than
TAG [44,45]. HSL is activated by phosphorylation mediat-
ed by protein kinase A (PKA), extracellular signal-regulat-
ed kinase (ERK), glycogen synthase kinase 3b (GSK-3b;
previously known as GSK-4), calmodulin-dependent ki-
nase II (CAMKII), as well as AMP-activated protein kinase
(AMPK) [46–48]. Lipolysis by HSL is also affected by PKA-
mediated phosphorylation of perlipin-1 at serines 81, 222,
and 276, which induces HSL binding and provides HSL
access to lipid droplets, thus increasing lipolysis [49,50].
Thompson et al. reported a twofold increase in HSL
mRNA in WAT and a similar elevation of free FAs in
serum from cancer patients, compared with normal con-
trols [25], an observation supported by subsequent studies
reporting significantly increased HSL mRNA and protein
expression in WAT of patients in the early phases of CAC
[51,52]. Increased HSL expression also corresponds with
increased hormone-stimulated lipolysis in isolated fat cells
from subcutaneous WAT of CAC patients that could be
prevented by an HSL-specific inhibitor, BAY [52].Adipose triglyceride lipase (ATGL)
ATGL was discovered by three independent groups in 2004
[53–55]. It belongs to a large family of patatin domain-
containing proteins, preferentially hydrolyzes TAG, and,
thus, catalyzes the first step of lipolysis that generates
DAG and a molecule of FA. Recently, Yang et al. showed
that overexpression of ATGL can compensate for HSL loss
during basal or TNF-a-stimulated lipolysis [56]. ATGL is
expressed in most human tissues with the highest levels in
WAT and BAT (brown adipose tissue). Recent studies have
convincingly established that ATGL catalyzes the rate-
limiting step of lipolysis in human as well as murine
adipose tissue [45].
ATGL levels are regulated by PPARg via the PPAR
responsive element (PPRE) present in its promoter [57],
ATGL is also regulated directly by its cofactor comparative
gene identification-58 (CGI-58) [58], a member of the a/b
hydrolase-fold containing subfamily. It activates ATGL by
direct interaction with the N-terminal domain of ATGL. The
C terminus of ATGL appears to have an inhibitory effect on
enzyme activity; it is, however, important for interactions
with lipid droplets. Full activation of ATGL by CGI-58
requires both protein–protein interaction with ATGL as
well as binding to a lipid droplet [44]. In addition to CGI-
58, Yang et al. recently showed that the protein G0S2 (G0/G1
switch gene 2) also regulates enzymatic activity of ATGL by
direct interaction [59]. Similar to ATGL, G0S2 is ubiqui-
tously expressed and localizes to mitochondria, lipid dro-
plets, the endoplasmic reticulum, and the cytosol. The N-
terminal domain of G0S2 interacts with the patatin domain
of ATGL, thereby restricting access of the enzyme to lipid
droplets and thus inhibiting ATGL activity [59].
Agustsson et al. have shown that Atgl expression is
somewhat enhanced in WAT of cachectic cancer patients;
however, the increase was not significant [52]. Given that
ATGL activity is post-translationally regulated by several
factors, mRNA expression does not always correspond to
enzyme activity. Using two murine cachexia models, our
group recently reported that ATGL activity increases in
parallel with tumor growth and WAT mobilization [18].
Atgl/mice were protected from tumor-induced lipolysis,
which preserved WAT mass. Analysis of WAT from cachec-
tic cancer patients showed significantly increased ATGL
activity that was strongly negatively correlated with BMI
[18]. In line with previous reports, wild type mice bearing
tumors presented with lipolysis and depletion of WAT
prior to skeletal muscle loss. Interestingly, in addition to
WAT, skeletal muscle was also preserved in tumor bearing
Atgl/ mice. Of note, ATGL is also expressed in skeletal
muscle and has been reported to play an important role in
regulating muscle lipid metabolism [60–62]. Therefore, it
remains to be investigated if the preservation of muscle is
an indirect effect of reduced levels of circulating free FA
and/or other factors released from WAT or if it is due to loss
of ATGL activity in muscle itself.
Modulators and regulators of triglyceride lipases in
cancer cachexia
Tumor necrosis factor-alpha (TNF-a)
Kawakami and Cerami noticed that lipopolysaccharide
(LPS) sensitive C3H/HeN mice, when injected with LPS,295
Box 2. Lipotoxicity
WAT functions as a reservoir for excess lipids and regulates the
supply of FA to various tissues for energy generation. This function
is deregulated in various metabolic syndromes, as well as in CAC,
potentially causing a lipid overload in other tissues. The concept of
lipotoxicity encompasses ectopic accumulation of fat or increased
exposure to FA, which has deleterious effects in several organs
including liver, heart, skeletal muscle, and pancreas [100,101].
Lipotoxicity occurs as a consequence of deregulated lipogenesis,
lipolysis, or lipid oxidation, and several reports link lipid metabolites
such as DAG, FAs, and ceramides to lipotoxicity. Skeletal muscle is
one of the main sites of lipid uptake and oxidation and myotubes
exposed to saturated FAs and ceramides show increased reactive
oxygen species (ROS) production that causes insulin resistance via
PKC and/or nuclear factor (NF)-kB signaling, and increased expres-
sion of inflammatory proteins and several myokines [101]. Both FAs
and ceramides can cause apoptosis in myocytes (lipoapoptosis)
[101].
Cachexia mobilizes FA from WAT via increased ATGL and HSL
activity, resulting in the exposure of various organs to excess FAs,
which might cause insulin insensitivity, mitochondrial dysfunction,
and apoptosis often observed in skeletal muscle of CAC patients.
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served that serum of endotoxin sensitive mice that had
been administered LPS suppressed LPL activity, even in
endotoxin-resistant mice [63]. Cerami and his group later
termed the factor produced in vitro by macrophages primed
with LPS, as well as other microbial substances that
suppressed LPL activity in isolated adipocytes, ‘cachectin’
[64]. Purified cachectin displayed tumor necrosis activity
in vitro, suggesting that cachectin was homologous to TNF-
a; indeed, N-terminal protein and DNA sequencing
revealed that these are the same, highly conserved protein
[65].
The onset of anorexia, anemia, weight loss, and loss of
body fat and muscle protein after administration of suble-
thal doses to healthy animals suggests that TNF-a plays a
central role in the development of cachexia. TNF-a has
been detected in serum from 36.5% of pancreatic carcinoma
patients, and the level inversely correlated with patient
BMI and body weight [66]. TNF-a is reported to suppress
the expression of LPL mRNA and LPL activity, along with
stimulating lipolysis in vitro and in vivo [67]. The mecha-
nism by which TNF-a increases lipolysis is still unknown,
although several hypotheses have been proposed. Com-
pared with lipolysis induced by hormones, lipolysis in-
duced by TNF-a is a slow process, taking 6–12 h to
reach a detectable level and achieving the maximum effect
after 48 h [56]. Interestingly, TNF-a downregulates the
expression of both ATGL and HSL in rodent adipocytes
[68–71]. Given that ATGL and HSL are the major lipases
present in adipocytes and drive 90% of TAG hydrolysis,
this indicates an indirect regulation of lipolysis by TNF-a.
In addition to regulating lipase expression, TNF-a induces
phosphorylation of perilipin-1, most likely by an increase
in cAMP levels that activates PKA [72]. This process might
also induce phosphorylation of HSL, which accelerates its
translocation to lipid droplets and, hence, increases lipoly-
sis. Recently, however, Yang et al. showed that ATGL
downregulation almost completely abolished glycerol re-
lease induced by TNF-a in 3T3-L1 adipocytes, whereas
ablation of HSL or the ATGL coactivator CGI-58 had only a
partial influence [56], suggesting an essential role for
ATGL in lipolysis induced by TNF-a. In addition, a sharp
decrease in G0S2 mRNA and protein levels was observed
that could be blocked by inhibiting proteasomal degrada-
tion using the protease inhibitor MG-132. G0S2 overex-
pression also significantly decreased lipolysis induced by
TNF-a [56].
Intraperitoneal administration of TNF-a antibodies in
two mice models of CAC, LLC and MCG-101, prevented
cachexia-associated features including the loss of WAT,
lean mass, and body weight and significantly reduced
tumor size, thus confirming previous reports on TNF-a
involvement in CAC progression [73]. However, antibody
treatment had no effect on profound anemia, hypoalbumi-
nemia, or the increase in serum amyloid P concentrations.
TNF receptor type I knockout mice with exponentially
growing LLC showed reduced WAT loss compared with
wild type controls [74], but the fact that CAC was not
completely prevented in TNF receptor type I knockout
mice led the authors to consider the involvement of other
cytokines or factors in the onset of cachexia. Mahony et al.296failed to identify TNF-a in tumor or serum from MAC16
bearing cachectic mice [75]. Moreover, circulating TNF-a
levels in cancer patients vary considerably and generally
do not correlate with weight loss in terminal cancer
patients [5]. Because of the very short half-life of TNF-a
and variations in sensitivities of the detection methods, it
might, however, be premature to draw a final conclusion. It
is also conceivable that the role of TNF-a in the progression
of cachexia might be limited to pre-cachexia and early
cachexia stages, but resolving the exact roles of TNF-a
will require further studies.
Interleukins
Similar to TNF-a, IL-6 also induces lipolysis in 3T3-L1
adipocytes as well as in primary mouse and human
adipocytes [76]. In addition, IL-6 decreases LPL activity
as well as perlipin A and PPARg mRNA expression in
3T3-L1 adipocytes. IL-6 treatment stimulates lipolysis
by activating ERK, but it does not elevate cAMP levels
and a PKA inhibitor had no effect on IL-6 stimulated
lipolysis [77].
Strassman et al. reported increased serum levels of IL-6,
but not TNF-a, in cachectic mice bearing C-26 murine colon
adenocarcinoma, which are reduced once the tumors are
resected [78]. In addition, monoclonal antibodies against
IL-6, but not TNF-a, improved body weight and conserved
WAT mass in C-26 bearing mice [78]. Recently, Tsoli et al.
confirmed previous reports and attributed deregulation of
lipid metabolism in BAT to elevated circulating IL-6 levels
in C-26 bearing cachectic mice [79]. Patients with non-
small-cell lung carcinoma (NSCLC) displaying weight loss
showed a significant increase in circulating IL-6 compared
with weight-stable NSCLC patients [80]. However, anoth-
er study did not find a correlation between TNF-a, IL-1, IL-
6, and weight loss of 61 terminal cancer patients [81]. Soda
et al. reported that a C-26 clone which did not induce
cachexia also enhanced IL-6 to the same level as the C-
26 clone that induced severe cachexia [82]. In agreement,
Inadara et al. reported that the factor causing depletion of
adipose tissue in C-26 tumor bearing mice is different from
Box 3. Adipose tissue–skeletal muscle crosstalk
WAT had been considered as a large, passive fuel reservoir of the
body supplying FAs to tissues such as skeletal muscle and the heart
for energy production. Findings in the past two decades established
WAT as one of the largest endocrine, as well as secretory organs,
producing several bioactive peptides in autocrine, paracrine, and
endocrine manners. Major adipocyte-derived factors with endocrine
potential, commonly referred to as adipokines, include leptin, TNF-
a, IL-6, monocyte chemotactic protein-1 (MCP-1), plasminogen
activator inhibitor-1 (PAI-1), adipsin, complement factor B, adipo-
nectin, nonesterified fatty acid (NEFA), and resistin [102,103]. In
addition to the production of adipokines, WAT also expresses
receptors for various endocrine hormones, nuclear hormones,
cytokines, and catecholamine [104].
Similarly, skeletal muscle has also been established to function as
an endocrine organ with the identification of several secretory
peptides commonly termed as myokines [105–107]. In addition to
the secretory proteins that might act in both paracrine and
endocrine manners, skeletal muscle also harbors receptors for
various hormones, FAs, cytokines, and other factors.
FAs, leptins, cytokines, and other adipokines may cause lipotoxic
effects in skeletal muscle [108]. Adipokines have been reported to
induce insulin resistance, impair muscle development, alter muscle
lipid and amino acid metabolism, and modify signaling, thus
affecting skeletal muscle mass [108]. Similarly, myokines produced
by skeletal muscle influence WAT metabolism and mass [109].
Because CAC is a complex disorder affecting WAT, skeletal
muscle, and other organs and tissues, it should be viewed from a
systemic point of view. Recent findings establish the paramount
importance of understanding the crosstalk among tumor, WAT, and
muscle for diagnosis and therapeutic intervention. Several recent
reports indicate that WAT is affected and depleted before skeletal
muscle loss can be detected by enhanced proteasome or caspase
activity [5]. Indeed, our findings in lipase knockout mice suggest that
preventing WAT loss might help to prevent skeletal muscle loss [18].
Review Trends in Molecular Medicine May 2013, Vol. 19, No. 5IL-6 or TNF-a [83], suggesting that IL-6 cannot be the only
factor causing cachexia in tumor bearing mice.
Zinc alpha glycoprotein (ZAG)
Aiming to characterize and isolate the lipid-mobilizing
factor(s) present in serum of cancer patients or tumor
bearing animals, Tisdale and coworkers identified a
factor identical to a known protein, zinc a2-glycoprotein
(ZAG), that is present in serum of mice bearing the
cachexia-inducing MAC16 tumor as well as in urine
and serum of CAC patients [84,85]. When injected into
mice, the factor caused increased lipolysis, imitating
tumor-induced cachexia [86]. ZAG is expressed by
tumors that induce severe cachexia in patients as well
as animal models of CAC [86]. It induces lipolysis and
loss of WAT by stimulating adenylyl cyclase in a GTP-
dependent process, which in turn activates HSL, thus
increasing TAG hydrolysis and mobilizing both FAs and
glycerol [5]. However, the effect of ZAG on ATGL, or the
involvement of ATGL in ZAG-stimulated lipolysis,
remains unknown. We identified a significant increase
of ZAG in tumor bearing wild type and Atgl/ mice, but
only wild type mice showed cachexia [18]. This warrants
a detailed investigation of the potential role of ZAG in
ATGL-mediated lipolysis.
In addition to various tumors, several tissues such as
WAT, BAT, heart, skeletal muscle, liver, and lung also
express and release ZAG. Both mRNA and protein expres-
sion of ZAG in WAT is increased in MAC16 bearing mice
and correlates with progressive loss of body weight [87].
Accordingly, Zag/ mice gained weight and WAT mass
when put on a high-fat diet, confirming the importance of
ZAG in regulating WAT metabolism. Basal lipolysis is not
affected in the adipocytes of Zag/ mice; however, they
showed decreased sensitivity towards isoprenaline-in-
duced lipolysis [88]. The effects of cachexia-inducing
tumors on WAT of Zag/ mice would be very interesting
to study.
G0/G1 switch gene 2 (G0S2)
G0S2 was first described by Russell and Forsdyke in
lymphocytes as a protein highly expressed between the
G0 and G1 phases of the cell cycle [89]. To date, there is
conflicting evidence of its role in cell-cycle regulation
[90,91]. G0S2 expression is not restricted to cancer tissue;
it is expressed in almost all normal human and murine
tissues. Zandbergen et al. nicely showed that the expres-
sion of G0S2 is tightly regulated by PPARa and PPARg
[92], as well as being influenced by nutritional status,
insulin, and TNF-a [59]. Liu and colleagues recently
reported that G0S2 interacts with cytosolic ATGL and
impedes its interaction with TAG, thus inhibiting TAG
hydrolysis [59]. Downregulation of G0S2 significantly in-
creased lipolysis and ATGL activity without affecting
ATGL expression [93]. G0S2, however, does not affect
the expression or activity of HSL [59]. It is interesting
to note that TNF-a/cachectin, which is elevated in the
serum of CAC patients, can reduce G0S2 expression and
thus increase lipolysis via changes in ATGL activity [56].
This supports the finding that ATGL is a key player in
mobilizing TAG reserves of adipose depots during CAC,despite the fact that the expression of ATGL is mostly
unaltered in WAT of CAC patients or animals. It would,
therefore, be of great interest to investigate G0S2 expres-
sion levels in WAT of CAC patients or in CAC animal
models.
Concluding remarks
CAC is now recognized to be a devastating syndrome in
cancer patients that results in a significant decrease of
WAT as well as muscle mass which cannot be reversed
with classical nutritional interventions. Increased circu-
lating cytokine levels and activated catabolic processes
underline the major pathological changes observed. Al-
though several factors and mechanisms associated with
CAC have been identified in the past decades, answers to
the basic question of how and why tumors cause cachexia
remain elusive (Box 1). In this review, we summarize
and put into perspective recent reports that indicate the
importance of lipolysis and TAG hydrolases in the devel-
opment of the syndrome. In CAC, increased activities of
major TAG hydrolases in WAT, namely, ATGL and HSL,
are observed, thus boosting lipolysis as evidenced by
increased circulatory glycerol and FAs that might, in
turn, harm other tissues and organs, an effect termed
lipotoxicity (Box 2). In addition, a significant reduction in
WAT LPL activity is reported, which explains increased
TAG levels in CAC patients. In summary, CAC reduces
WAT mass by downregulating anabolic metabolism297
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Figure 2. Importance of white adipose tissue (WAT)–skeletal muscle crosstalk in cancer associated cachexia (CAC) and/or lipotoxicity. Factors released by tumors induce lipolysis
in WAT (Figure 1) and alter adipokine secretion by WAT. As outlined in Figure 1, tumor necrosis factor-a (TNF-a), through the TNF receptor and G0S2 (G0/G1 switch gene 2),
regulates the activity of the lipases adipose triglyceride lipase (ATGL), hormone sensitive lipase (HSL), and monoglyceride lipase (MAGL). Leptin and adiponectin released by WAT
act through the leptin receptor (LR) or the adiponectin receptor (ADIPOR) present on myocytes and activates AMP-activated protein kinase (AMPK), which, in turn, activates ATGL.
Catecholamines signal through the b-adrenoceptor and phosphorylate HSL. Fatty acids (FAs) released by adipocytes as a result of increased lipolysis are transported into myocytes
by FA transporters such as FATP1 and CD36. FAs are b-oxidized in mitochondria, generating reactive oxygen species (ROS), and, in turn, cause cell death by apoptosis often seen in
lipotoxicity and cachexia. Both FAs and ceramides induce stress in the endoplasmic reticulum (ER stress). ER stress activates PERK, which phosphorylates the ribosome binding
protein elF2a and thus downregulates protein synthesis, as is often seen in lipotoxicity and cachexia. FAs are also converted into diacylglycerol (DAG), which along with ceramides
activate protein kinase C (PKC). PKC activates the nuclear factor (NF)-kB pathway. This downregulates MyoD and increases the ubiquitin ligases, MURF1 and MAFBx, thus leading
to protein degradation through activation of the proteasome complex. PKC also phosphorylates JNK (c-Jun N-terminal kinase). Activated JNK along with PKC phosphorylates IRS-1
at serine residue 1101, which leads to insulin resistance because of decreased PI3K/Akt activity. Decreased Akt and increased TNF-a signaling increases expression of MAFBx and
MURF1 through FOXO, which also leads to increased protein degradation. Factors in red are upregulated in cachexia, those in green are downregulated in cachexia, and factors
shown in black have no change or have not yet been determined in cachexia. Solid lines indicate pathways confirmed in CAC and dotted lines expected but unconfirmed ones.
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lipids.
Of the greatest clinical relevance, CAC severely reduces
skeletal muscle mass in cancer patients leading to atrophy
and loss of muscle function. Several factors released by
tumors, including various cytokines, induce proteolysis
and muscle catabolism, leading to atrophy. Of note, recent
reports point to the importance of WAT–muscle interac-
tions in CAC. WAT is affected earlier than the effects of
CAC can be observed in skeletal muscle. This might reflect
a sequential progression of cachexia rather than a sto-
chastic phenomenon. Both WAT and muscle have recently
been recognized to have important endocrine functions
secreting various factors commonly termed adipokines
and myokines (Box 3). Fat–muscle crosstalk has been
investigated intensively in metabolic syndromes such as
obesity and diabetes, and reports frequently show lipo-
toxic cell death as well as insulin resistance as a result
(Boxes 2 and 3). The existence and importance of fat–
muscle crosstalk in the initiation and/or progression of
CAC remains to be uncovered. Figure 2 summarizes the
possible WAT–muscle crosstalk leading to skeletal muscle
atrophy.
It is very likely that the diversity of genetic and
epigenetic changes occurring in different tumors results
in diverse effects on tumor metabolism. Therefore, it is
not that surprising that great variety is observed in the
induction, progression, and severity of CAC, and it is
equally likely that several different mechanisms contrib-
ute to CAC development. An exact delineation of these
processes will be necessary to devise novel and improved
treatment strategies to combat this devastating
condition.
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